PMO-175 Can a 3-month “stopping rule” for pegylated-interferon-α be applied to a UK population of chronic hepatitis B infected patients of mixed genotype? | Gut

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via BSG

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Article info

Posters

Viral hepatitis

PMO-175 Can a 3-month “stopping rule” for pegylated-interferon-α be applied to a UK population of chronic hepatitis B infected patients of mixed genotype?

Free

Authors

U S Gill PubMed articles Google scholar articles
L Payaniandy PubMed articles Google scholar articles
J Schulz PubMed articles Google scholar articles
V Ross PubMed articles Google scholar articles
Y Kallis PubMed articles Google scholar articles
P Kooner PubMed articles Google scholar articles
R Marley PubMed articles Google scholar articles
I Ushiro-Lumb PubMed articles Google scholar articles
G R Foster PubMed articles Google scholar articles
P T F Kennedy PubMed articles Google scholar articles

Citation

Gill US, Payaniandy L, Schulz J, et al

PMO-175 Can a 3-month “stopping rule” for pegylated-interferon-α be applied to a UK population of chronic hepatitis B infected patients of mixed genotype?

Gut 2012;61:A145.

Publication history

First published May 28, 2012.

Online issue publication

April 18, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.